Work

Genomic-based predictive biomarkers to anti-HER2 therapies: A combined analysis of CALGB 40601 (Alliance) and PAMELA clinical trials.

Year: 2019

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2019.37.15_suppl.571

Authors: Aranzazu Fernandez-Martinez, Maki Tanioka, Cheng Fan, Joel S. Parker, Katherine A. Hoadley, Ian E. Krop, Javier Cortes, Antonio Llombart Cussac, Paolo Nuciforo, Patricia Galván, Tomas Pascual, Ann H. Partridge, Aleix Prat, Lisa A. Carey, Charles M. Perou

Institutions: University of North Carolina at Chapel Hill, Dana-Farber Cancer Institute, Vall d'Hebron Institute of Oncology, IDCQ Hospitales y Sanidad, S.L.U., Hospital Arnau de Vilanova, Hospital Clínic de Barcelona, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Solti

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2947290625

Cites:

Cited by: 7

Related to: 10